- |||||||||| rivastigmine / generics
Preclinical, Journal: Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. (Pubmed Central) - Mar 29, 2019 Moreover, rivastigmine demonstrated a P-gp expression dependent neuroprotective effect that was highest in APP(+)/mdr1(+/+)>APP(+)/mdr1(+/-)>APP(+)/mdr1(-/-) as determined by expression of synaptic markers PSD-95 and SNAP-25 using Western blot analysis. Collectively, our results suggest that P-gp plays important role in mediating rivastigmine non-cholinergic beneficial effects, including Aβ brain load reduction, neuroprotective and anti-inflammatory effects in the AD mouse models.
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
Clinical, Journal: Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. (Pubmed Central) - Mar 29, 2019 The present study suggests that despite a relatively lower dose of ChEI after the switch, switching from donepezil or rivastigmine preserved cognitive functions for at least 6 M. Switching from galantamine to rivastigmine improved Mini-Mental State Examination and ABS at 3 M, but did not improve ADL scores. Geriatr Gerontol Int 2017; 17: 1843-1848.
- |||||||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial primary completion date: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Dec 5, 2018 P3, N=721, Active, not recruiting, Geriatr Gerontol Int 2017; 17: 1991-1999. N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019
- |||||||||| rivastigmine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CHEVAL: Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease (clinicaltrials.gov) - Oct 10, 2018 P4, N=91, Terminated, N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019 N=168 --> 91 | Trial completion date: Dec 2022 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2018; enrollment to slow, insufficient funds
- |||||||||| donepezil / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly (clinicaltrials.gov) - Jun 13, 2018 P4, N=170, Active, not recruiting, N=168 --> 91 | Trial completion date: Dec 2022 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2018; enrollment to slow, insufficient funds Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated, Trial primary completion date: Dec 2019 --> Dec 2021 N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Phase classification, Enrollment change: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017 P1, N=389, Completed, No longer recruiting --> Completed Phase classification: P3 --> P1 | N=80 --> 389
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial completion, Enrollment change, Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 17, 2017 P3, N=80, Completed, Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Enrollment change, Trial termination, HEOR: COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) - Apr 14, 2016 P=N/A, N=200, Terminated, The trial was terminated at Stage 1; did not proceed to Stage 2. N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Adverse events: A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease (clinicaltrials.gov) - Apr 14, 2016 P=N/A, N=57, Completed, N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early. Recruiting --> Completed | N=180 --> 57 | Trial primary completion date: Dec 2018 --> Jan 2016
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jun 11, 2015 P3, N=500, Recruiting, Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Apr 2016
- |||||||||| rivastigmine / Generic mfg.
Trial completion, Trial primary completion date: Rivastigmine and Huperzine A as Treatments for Cocaine Dependence (clinicaltrials.gov) - Jan 28, 2015 P1, N=72, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: May 2013 --> Jun 2014
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Enrollment closed, Trial primary completion date, HEOR: COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) - Dec 17, 2014 P=N/A, N=300, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Nov 2013 | Trial primary completion date: Aug 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Oct 2015
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014 P3, N=500, Recruiting, Trial completion date: Sep 2014 --> May 2015 Trial primary completion date: May 2014 --> May 2015
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014 P3, N=500, Recruiting, Trial primary completion date: May 2014 --> May 2015 Trial completion date: May 2014 --> May 2016
|